Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
McKinsey
Baxter
Medtronic
Mallinckrodt

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208843

See Plans and Pricing

« Back to Dashboard

NDA 208843 describes SIKLOS, which is a drug marketed by Addmedica Sas and is included in one NDA. It is available from one supplier. Additional details are available on the SIKLOS profile page.

The generic ingredient in SIKLOS is hydroxyurea. There are ten drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the hydroxyurea profile page.
Summary for 208843
Tradename:SIKLOS
Applicant:Addmedica Sas
Ingredient:hydroxyurea
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 208843
Suppliers and Packaging for NDA: 208843
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SIKLOS hydroxyurea TABLET;ORAL 208843 NDA Medunik 71770-100 71770-100-60 1 BOTTLE in 1 CARTON (71770-100-60) > 60 TABLET, FILM COATED in 1 BOTTLE
SIKLOS hydroxyurea TABLET;ORAL 208843 NDA Medunik 71770-120 71770-120-30 1 BOTTLE in 1 CARTON (71770-120-30) > 30 TABLET, FILM COATED in 1 BOTTLE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength100MG
Approval Date:Dec 21, 2017TE:RLD:Yes
Regulatory Exclusivity Expiration:Dec 21, 2020
Regulatory Exclusivity Use:NEW PRODUCT
Regulatory Exclusivity Expiration:Dec 21, 2024
Regulatory Exclusivity Use:TO REDUCE THE FREQUENCY OF PAINFUL CRISES AND TO REDUCE THE NEED FOR BLOOD TRANSFUSIONS IN PEDIATRIC PATIENTS, 2 YEARS OF AGE AND OLDER, WITH SICKLE CELL ANEMIA WITH RECURRENT MODERATE TO SEVERE PAINFUL CRISIS

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength1GM
Approval Date:Dec 21, 2017TE:RLD:Yes
Regulatory Exclusivity Expiration:Dec 21, 2020
Regulatory Exclusivity Use:NEW PRODUCT

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Johnson and Johnson
Harvard Business School
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.